Mouse soluble CD14 truncated at amino acid 71 in transgenic mice: Preventive effect on endotoxin-mediated toxic shock

Pathobiology

Volumn 70, Issue 2, 2002, Pages 103-114

  Higuchi, Yasunori ^a   Hijiya, Naoki ^a   Matsuura, Keiko ^a   Yasui, Atsushi ^a   Uchida, Tomohisa ^a   Yamamoto, Shunsuke ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

CD14; Shwartzman reaction; Soluble CD14; Transgenic mice

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMINO ACID; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; ENDOTOXIN; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; PEPTONE; TUMOR NECROSIS FACTOR ALPHA; TURPENTINE OIL;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FUSION GENE; LETHALITY; LIVER; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM EXUDATE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SEPTIC SHOCK; SHWARTZMAN PHENOMENON; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIGENS, CD14; ASCITIC FLUID; BLOTTING, NORTHERN; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; IRRITANTS; LIPOPOLYSACCHARIDES; LIVER; MACROPHAGES, PERITONEAL; MICE; MICE, TRANSGENIC; NEUTROPHILS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SHOCK, SEPTIC; SHWARTZMAN PHENOMENON; TUMOR NECROSIS FACTOR-ALPHA; TURPENTINE; UP-REGULATION;

MUS MUSCULUS;

EID: 0036902521     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067310     Document Type: Article

References (46)

1. Akira S: Toll-like receptors and innate immunity. Adv Immunol 2001;78:1-56.
2. Medzhitov R, Janeway C Jr: The toll receptor family and microbial recognition. Trends Microbiol 2000;8:452-456.
3. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS-binding protein. Science 1990;249:1431-1433.
4. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide-binding protein. Science 1990;249:1429-1431.
5. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM: Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996;4:407-414.
6. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD: Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992;176:1665-1671.
7. Haziot A, Rong GW, Silver J, Goyert SM: Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J Immunol 1993;151:1500-1507.
8. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS: Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993;90:2744-2748.
9. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM: Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995;154:6529-6532.
10. Leturcq DJ, Moriarty AM, Talbott G, Winn RK, Martin TR, Ulevitch RJ: Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1996;98:1533-1538.
11. Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ: Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998;95:13875-13880.
12. Tamura Y, Higuchi Y, Kataoka M, Akizuki S, Matsuura K, Yamamoto S: CD14 transgenic mice expressing membrane and soluble forms: Comparisons of levels of cytokines and lethalities in response to lipopolysaccharide between transgenic and non-transgenic mice. Int Immunol 1999;11:333-339.
13. Juan TS, Hailman E, Kelley MJ, Busse LA, Davy E, Empig CJ, Narhi LO, Wright SD, Lichenstein HS: Identification of a lipopolysaccharide-binding domain in CD14 between amino acids 57 and 64. J Biol Chem 1995;270:5219-5224.
14. Matsuura K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, Yamamoto S: Upregulation of mouse CD14 expression in Kupffer cells by lipopolysaccharide. J Exp Med 1994;179:1671-1676.
15. Adachi Y, Satokawa C, Saeki M, Ohno N, Tamura H, Tanaka S, Yadomae T: Inhibition by a CD14 monoclonal antibody of lipopolysaccharide binding to murine macrophages. J Endotoxin Res 1999;5:139-146.
16. Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I: Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996;183:581-587.
17. Setoguchi M, Higuchi Y, Yoshida S, Nasu N, Miyazaki Y, Akizuki S, Yamamoto S: Insertional activation of N-myc by endogenous Moloney-like murine retrovirus sequences in macrophage cell lines derived from myeloma cell line-macrophage hybrids. Mol Cell Biol 1989;9:4515-4522.
18. Ray BK, Gao X, Ray A: Expression and structural analysis of a novel highly inducible gene encoding alpha 1-antitrypsin in rabbit. J Biol Chem 1994;269:22080-22086.
19. Matesic LE, Niemitz EL, De Maio A, Reeves RH: Quantitative trait loci modulate neutrophil infiltration in the liver during LPS-induced inflammation. FASEB J 2000;14:2247-2254.
20. Juan TS, Kelley MJ, Johnson DA, Busse LA, Hailman E, Wright SD, Lichenstein HS: Soluble CD14 truncated at amino acid 152 binds lipopolysaccharide (LPS) and enables cellular response to LPS. J Biol Chem 1995;270:1382-1387.
21. Yu W, Soprana E, Cosentino G, Volta M, Lichenstein HS, Viale G, Vercelli D: Soluble CD14(1-152) confers responsiveness to both lipoarabinomannan and lipopolysaccharide in a novel HL-60 cell bioassay. J Immunol 1998;161:4244-4251.
22. Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J Biol Chem 1995;270:17237-17242.
23. Stelter F, Bernheiden M, Menzel R, Jack RS, Witt S, Fan X, Pfister M, Schutt C: Mutation of amino acids 39-44 of human CD14 abrogates binding of lipopolysaccharide and Escherichia coli. Eur J Biochem 1997;243:100-109.
24. Stelter F, Loppnow H, Menzel R, Grunwald U, Bernheiden M, Jack RS, Ulmer AJ, Schutt C: Differential impact of substitution of amino acids 9-13 and 91-101 of human CD14 on soluble CD14-dependent activation of cells by lipopolysaccharide. J Immunol 1999;163:6035-6044.
25. Viriyakosol S, Kirkland TN: A region of human CD14 required for lipopolysaccharide binding. J Biol Chem 1995;270:361-368.
26. Setoguchi M, Nasu N, Yoshida S, Higuchi Y, Akizuki S, Yamamoto S: Mouse and human CD14 (myeloid cell-specific leucine-rich glycoprotein) primary structure deduced from cDNA clones. Biochim Biophys Acta 1989;1008:213-222.
27. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-733.
28. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD, et al: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-736.
29. Bazil V, Strominger JL: Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J Immunol 1991;147:1567-1574.
30. Galanos C, Freudenberg MA, Jay F, Nerkar D, Veleva K, Brade H, Strittmatter W: Immunogenic properties of lipid A. Rev Infect Dis 1984;6:546-552.
31. Gorgen I, Hartung T, Leist M, Niehorster M, Tiegs G, Uhlig S, Weitzel F, Wendel A: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol 1992;149:918-924.
32. Howard M, Muchamuel T, Andrade S, Menon S: Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-1208.
33. Bucklin SE, Silverstein R, Morrison DC: An interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality. Infect Immun 1993;61:3184-3189.
34. Welborn MB 3rd, Van Zee K, Edwards PD, Pruitt JH, Kaibara A, Vauthey JN, Rogy M, Castleman WL, Lowry SF, Kenney JS, Stuber D, Ettlin U, Wipf B, Loetcher H, Copeland EM, Lesslauer W, Moldwer LL: A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. J Exp Med 1996;184:165-171.
35. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-552.
36. Watanabe S, Mukaida N, Ikeda N, Akiyama M, Harada A, Nakanishi I, Nariuchi H, Watanabe Y, Matsushima K: Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF. Int Immunol 1995;7:1037-1046.
37. Suitters AJ, Foulkes R, Opal SM, Palardy JE, Emtage JS, Rolfe M, Stephens S, Morgan A, Holt AR, Chaplin LC, Shaw NE, Nesbitt AM, Bodmer MW: Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock. J Exp Med 1994;179:849-856.
38. Le Roy D, Di Padova F, Tees R, Lengacher S, Landmann R, Glauser MP, Calandra T, Heumann D: Monoclonal antibodies to murine lipopolysaccharide (LPS)-binding protein (LBP) protect mice from lethal endotoxemia by blocking either the binding of LPS to LBP or the presentation of LPS/LBP complexes to CD14. J Immunol 1999;162:7454-7460.
39. Nassif X, Mathison JC, Wolfson E, Koziol JA, Ulevitch RJ, So M: Tumour necrosis factor-alpha antibody protects against lethal meningococcaemia. Mol Microbiol 1992;6:591-597.
40. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990;145:3762-3766.
41. Verbon A, Dekkers PE, ten Hove T, Hack CE, Pribble JP, Turner T, Souza S, Axtelle T, Hoek FJ, van Deventer SJ, van der Poll T: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001;166:3599-3605.
42. Landmann R, Reber AM, Sansano S, Zimmerli W: Function of soluble CD14 in serum from patients with septic shock. J Infect Dis 1996;173:661-668.
43. Jin H, Yang R, Marsters S, Ashkenazi A, Bunting S, Marra MN, Scott RW, Baker JB: Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest 1995;95:1947-1952.
44. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJ: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996;184:1601-1608.
45. Roth RI, Su D, Child AH, Wainwright NR, Levin J: Limulus antilipopolysaccharide factor prevents mortality late in the course of endotoxemia. J Infect Dis 1998;177:388-394.
46. Dankesreiter S, Hoess A, Schneider-Mergener J, Wagner H, Miethke T: Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol 2000;164:4804-4811.